Motl: LY900003-A novel compound for the treatment of non-small cell lung cancer treatment of non-small cell lung cancer. Available at www.nice.org.uk Nemunaitis J, Holmlund JT, Kraynak M, Richards D, Bruce J, Ognoskie N et al, (1999) Phase I evaluation of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase c-alpha, in patients with advanced cancer. J Clin Oncol 17, 3586-3595. Patel AM, Dunn WF, Trastek VF, (1993) Staging systems of lung cancer. Mayo Clin Proc 68, 475-482. Peterson K, Moore JK, (2003) Cancer drugs in clinical development LY900003 (ISIS 3521). ISIS Pharmaceuticals website.Available at www.isispharm.com/press/press02/100102MfgAffinitac.htm. Ritch PS, Belt R, George S, Valdivieso M, Figueroa J, McCachren S et al, (2002) Phase I/II trial of ISIS 3521/ LY900003, an antisense inhibitor of PKC-alpha with cisplatin and gemcitabine in advanced non-small cell lung cancer (NSCLC). Poster presented at, The American Society of Clinical Oncology Orlando, FL, May 18-21. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J et al, (2002) Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N Engl J Med 346, 92-98. Sikic BI, Yuen AR, Advani R, Fisher G, Halsey J, Geary R et al, (1999) A phase I trial of ISIS 3521 (ISI 641 A) an antisense inhibitor of protein kinase C alpha combined with carboplatin and paclitaxel in patients with cancer. Poster presented at, The American Society of Clinical Oncology, Atlanta, GA, May 15-18. Sikic BI, Yuen, AR, Halsey J, Fisher GA, Pribble JB, Smith RM et al, (1997) A phase I trial of an antisense oligonucleotide targeted to protein kinase C-alpha (ISIS 3521) delivered by 21-day continuous intravenous infusion. Poster presented at, The American Society of Clinical Oncology, Denver, CO, May 17-20. Stewart L ( 1995) Chemotherapy in non-small cell lung cancer, a meta-analysis using updated data on individual patients from 52 randomized trials. BMJ 311, 899-909. Tamm I, Dorken B, Hartmann G, (2001) Antisense therapy in oncology, new hope for an old idea? Lancet 358, 489-497.
Tolcher AW, Reyno L, Venner PM, Ernst SD, Moore M, Geary RS et al, ( 2002) A randomized phase II and pharmacokinetic study of the antisense oligonucleotides ISIS 3521 and ISIS 5132 in patients with hormone-refractory prostate cancer. Clin Cancer Res 8, 2530-2535. Yuen AR, Halsey J, Fisher GA, Holmlund JT, Geary RS, Kwoh TJ et al, (1999) Phase I study of an antisense oligonucleotide to protein kinase c-! (ISIS 3521/CGP 64128A) in patients with cancer. Clin Cancer Res 5, 3357-3363. Yuen A, Advani R, Fisher G, Halsey J, Lum B, Geary R et al, (2000) A phase I/II trial of ISIS 3521, an antisense inhibitor of protein kinase C alpha, combined with carboplatin and paclitaxel in patients with non-small cell lung cancer. Poster presented at, The American Society of Clinical Oncology, New Orleans, LA, May 20-23. Yuen A, Halsey J, Fisher G, Advani R, Moore M, Saleh M et al, (2001) A phase I/II trial of ISIS 3521, an antisense inhibitor of PKC-alpha, with carboplatin and paclitaxel in patients with non-small cell lung cancer (Meeting abstract). Poster presented at, The American Society of Clinical Oncology, San Francisco, CA, May 12-15.
Dr. Susannah E. Motl
244